Showing results (311-320 of 328) with videos related to

Sort By:
Pageof 33
Blood|November 26, 1999
Interferon-alpha before allogeneic bone marrow transplantation in chronic myelogenous leukemia does not affect outcome adversely, provided it is discontinued at least 90 days before the procedureR Hehlmann, A Hochhaus, H J Kolb, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 26, 2017
Allogeneic hematopoietic cell transplantation in intermediate risk acute myeloid leukemia negative for FLT3-ITD, NPM1- or biallelic CEBPA mutationsK Heidrich, C Thiede, K Schäfer-Eckart, et al.
Bone Marrow Transplantation|January 14, 2009
Allogeneic hematopoietic SCT for patients with autoimmune diseasesT Daikeler, T Hügle, D Farge, et al.
British Journal of Haematology|June 8, 2004
Haematopoetic stem cell transplantation for refractory autoimmune cytopeniaJ R Passweg, M Rabusin, M Musso, et al.
Journal of Dairy Science|October 20, 2023
Prediction of key milk biomarkers in dairy cows through milk mid-infrared spectra and international collaborationsC Grelet, T Larsen, M A Crowe, et al.
Leukemia|August 19, 2015
Clofarabine salvage therapy before allogeneic hematopoietic stem cell transplantation in patients with relapsed or refractory AML: results of the BRIDGE trialJ M Middeke, R Herbst, S Parmentier, et al.
Leukemia|December 2, 2014
Hematopoietic cell transplantation in patients with intermediate and high-risk AML: results from the randomized Study Alliance Leukemia (SAL) AML 2003 trialJ Schetelig, M Schaich, K Schäfer-Eckart, et al.
Blood Cancer Journal|January 16, 2016
Karyotype complexity and prognosis in acute myeloid leukemiaF Stölzel, B Mohr, M Kramer, et al.
Bone Marrow Transplantation|July 1, 1997
German consensus on immunogenetic donor search for transplantation of allogeneic bone marrow and peripheral blood stem cellsH D Ottinger, E Albert, R Arnold, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 2, 2018
Intermediate-dose cytarabine plus mitoxantrone versus standard-dose cytarabine plus daunorubicin for acute myeloid leukemia in elderly patientsC Röllig, M Kramer, M Gabrecht, et al.
Pageof 33